dsaek

DSAEK
  • 文章类型: Journal Article
    目的:报道慢凝连续波经巩膜睫状体光凝(CW-TSCPC)治疗药物治疗难治性角膜移植术后青光眼的疗效。
    方法:回顾性纳入47例患者(平均年龄70.7±15.7岁,随访13.9±7.1个月)的病历。所有患者均在穿透性角膜移植术(PKP;n=28)或Descemet剥离自动内皮角膜移植术(DSAEK;n=19)后诊断为继发性青光眼,既往无切口性青光眼或TSCPC手术史。研究参与者接受了缓慢凝血CW-TSCPC(1250毫瓦功率和4秒持续时间)。
    结果:观察到IOP从术前31.8±8.0mmHg到术后16.9±9.0mmHg(p<0.001)的静态显着降低。同样,青光眼用药数量从4.0±1.0降至2.7±1.4(p<0.001).12个月和24个月的总体成功率分别为68.1%和66.0%,分别,PKP后和DSAEK后亚组之间的成功率没有差异(p=0.836)。未观察到VA或中央角膜厚度(CCT)的显着变化(分别为p=0.345和0.311)。1例(3.3%)患者有移植物排斥反应。在这项研究中注意到的大多数并发症是轻度和短暂的。
    结论:我们的研究表明,对于医学上未控制的角膜移植术后青光眼患者,慢凝TSCPC可能是一种安全有效的手术治疗青光眼的方式。
    OBJECTIVE: To report the outcomes of slow-coagulation continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) in post-keratoplasty glaucoma refractory to medical therapy.
    METHODS: Medical records of 47 patients (mean age of 70.7 ± 15.7 years and follow-up of 13.9 ± 7.1 months) were retrospectively enrolled. All patients had the diagnosis of secondary glaucoma after penetrating keratoplasty (PKP; n = 28) or Descemet\'s stripping automated endothelial keratoplasty (DSAEK; n = 19) with no previous history of incisional glaucoma or TSCPC surgeries. Study participants underwent slow-coagulation CW-TSCPC (1250-milliwatt power and 4-second duration).
    RESULTS: A statically significant reduction of IOP from 31.8 ± 8.0 mmHg preoperatively to 16.9 ± 9.0 mmHg postoperatively was noted (p < 0.001). Similarly, the number of glaucoma medications decreased from 4.0 ± 1.0 to 2.7 ± 1.4 (p < 0.001). The overall success rates at 12 and 24 months were 68.1% and 66.0%, respectively, with no difference in success rates between post-PKP and post-DSAEK subgroups (p = 0.836). No significant changes in VA or central corneal thickness (CCT) were observed (p = 0.345 and 0.311, respectively). One (3.3%) patient had a graft rejection. The majority of the complications noted during this study were mild and transient.
    CONCLUSIONS: Our study suggests that slow-coagulation TSCPC may be a safe and efficient surgical glaucoma treatment modality in patients with medically uncontrolled post-keratoplasty glaucoma.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:回顾已发表的关于DSAEK/DSEK和DMEK治疗失败的穿透性角膜移植术的适应证和结果的文献。
    方法:这是一项系统综述和单臂荟萃分析。
    方法:文献检索在PubMed,Embase,WebofScience,和Cochrane系统评价数据库。纳入了穿透性角膜移植术失败后DSAEK/DSEK或DMEK的前瞻性和回顾性研究。主要结果指标是移植物存活率和脱离率,以及术后视觉结果。
    结果:共纳入25项研究,涉及970名患者/989只眼,包括735例746眼接受DSAEK/DSEK手术的患者和235例243眼接受DMEK手术的患者,所有这些都遵循先前失败的PK。没有随机对照研究。在所有的DSAEK-PK研究中,移植物失败率为18%(10%,26%),脱离率为15%(9%,22%),排斥率为7%(3%,12%)由末次随访时间。在所有的DMEK-PK研究中,移植物失败率为14%(4%,27%),脱离率为42%(28%,56%),排斥率为7%(2%,16%)。DSAEK-PK和DMEK-PK组的平均视力为0.65±0.18和0.43±0.23logMAR,分别,术后6个月。
    结论:内皮角膜移植术用于治疗失败的穿透性角膜移植术可改善大多数受者的视力和移植物透明度。尽管两组之间的移植物存活率和排斥率相当,DMEK-PK组的视觉结局更好,脱离率更高.
    OBJECTIVE: To review the published literature on indications and outcomes of DSAEK/DSEK and DMEK for the treatment of failed penetrating keratoplasty.
    METHODS: This is a systematic review and single-arm meta-analysis.
    METHODS: Literature searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews. Prospective and retrospective studies reporting DSAEK/DSEK or DMEK after failed penetrating keratoplasty were included. Primary outcome measures are graft survival and detachment rates, as well as postoperative visual outcomes.
    RESULTS: A total of 25 studies with 970 patients/989 eyes were included, comprising 735 patients with 746 eyes which underwent DSAEK/DSEK surgery and 235 patients with 243 eyes which underwent DMEK surgery, all of them following a previously failed PK. There were no randomized controlled studies. In all of the DSAEK-PK studies, the graft failure rate was 18% (10%, 26%), the detachment rate was 15% (9%, 22%) and the rejection rate was 7% (3%, 12%) by the time of the last follow-up. And in all of the DMEK-PK studies, the graft failure rate was 14% (4%, 27%), the detachment rate was 42% (28%, 56%) and the rejection rate was 7% (2%, 16%). The mean visual acuity of the DSAEK-PK and DMEK-PK groups is 0.65 ± 0.18 and 0.43 ± 0.23 logMAR, respectively, at 6 months postoperatively.
    CONCLUSIONS: Endothelial keratoplasty for treatment of failed penetrating keratoplasty led to improved vision and graft clarity in most recipients. Though graft survival rates and rejection rates were comparable between the two groups, the DMEK-PK group showed better visual outcomes with higher detachment rate.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    这项研究的目的是回顾已发表的发病率,病因学,板层角膜移植术后发生感染性界面角膜炎(IIK)患者的临床特征和治疗。
    本研究为系统文献综述。
    我们通过PubMed搜索,使用以下术语对已发表的中文和英文报告进行了系统回顾:角膜移植,角膜移植术,前板层角膜移植术(ALK),深前板层角膜移植术(DALK),深板层内皮角膜移植术(DLEK),Descemet膜内皮角膜移植术(DMEK),Descemet剥离内皮角膜移植术(DSEK),Descemet剥离自动内皮角膜移植术(DSAEK),感染性界面角膜炎(IIK),真菌性角膜炎,和细菌性角膜炎。收集的数据包括患者人口统计学,外科技术,临床体征,治疗,结果,和捐赠者的边缘文化。还对相关文献进行了回顾。
    从2007年到2月2018年,我们确定了板层角膜手术后IIK的62例。DALK/ALK组平均年龄26.95±8.80岁,男女比例11:8,DSAEK/DSEK/DMEK组平均年龄69.65±8.00岁,男女比例17:16(10例无性别信息)。在62个案例中,46例(75.41%)为真菌,9例(14.75%)为细菌性,放线菌属2例(3.28%),1例(1.64%)为棘阿米巴,不确定者4例(6.56%)。DALK/ALK组患者症状平均发病天数(POD)49.47±48.56,EK组53±112.01,细菌性角膜炎为62.44±50.07,真菌性角膜炎为51.5±102.42。术后随访时间DALK/ALK组平均10.10±9.36个月,DSAEK/DSEK/DMEK组平均12.37±12.28个月。在总共62个案例中,1例(1.61%)肺炎克雷伯菌阳性供体边缘培养物与IIK中的相同病原体有关,在IIK中,有16例(25.81%)的真菌阳性供体边缘培养物与相同的病原体相关。临床症状包括结膜注射,接口不透明度,细菌性角膜炎的基质水肿,在某些真菌性角膜炎的病例中,在与内皮斑块的界面处有密集的白色浸润。药物治疗包括局部和口服抗微生物剂。手术干预包括治疗性角膜移植术。15例(24.19%),医疗管理是成功的。在剩下的47个案例中,8例(12.90%)接受了重复的板层角膜移植术(LK),39例(62.90%)对保守药物治疗无反应,并接受了治疗性角膜移植术(TKP)。感染后最佳矫正视力(BCVA)为7眼logMAR0(11.29%),20只眼睛中大于或等于logMAR0.4(32.26%),22只眼小于logMAR0.4(35.48%),13只眼小于logMAR0.7(20.97%)。在边缘培养阴性组(n=19)中,平均BCVA为logMAR0.59±0.68,边缘培养阳性组为logMAR0.44±0.74(n=15)。在术后随访期间,有3例DMEK术后复发。
    感染性界面角膜炎(IIK)是板层角膜移植术的罕见并发症,但它可能会导致视力严重丧失或永久性失明。虽然移植物感染可在手术后的任何时间发生,最常见(87%)发生在术后前3个月(54/62例)。板层角膜移植术后最常见的IIK致病生物是白色念珠菌。阳性边缘培养结果可以提供针对所鉴定的生物体的更快速和适当的治疗。治疗性角膜移植术(TKP)是治疗IIK的最常见外科手术。TKP后的视觉结果是公平的,32.26%(20/62)的患者获得LogMAR0.4或更高。
    The purpose of this study was to review the published incidence, etiology, clinical features and management of patients who developed infectious interface keratitis (IIK) following lamellar keratoplasty.
    This study is a systematic literature review.
    We conducted a systematic review of published Chinese and English report through a PubMed search with the medical subject headings using the following terms: corneal transplantation, keratoplasty, anterior lamellar keratoplasty (ALK), deep anterior lamellar keratoplasty (DALK), deep lamellar endothelial keratoplasty (DLEK), Descemet membrane endothelial keratoplasty (DMEK), Descemet stripping endothelial keratoplasty (DSEK), Descemet stripping automated endothelial keratoplasty (DSAEK), infectious interface keratitis (IIK), fungal keratitis, and bacterial keratitis. Data collected included patient demographics, surgical technique, clinical signs, treatment, outcomes, and donor rim cultures. A review of the relevant literatures was also undertaken.
    From 2007 to Feb. 2018, we identified 62 cases of IIK following lamellar corneal surgery. The mean age was 26.95 ± 8.80 years with a male/female ratio of 11:8 in DALK/ALK group and 69.65 ± 8.00 years with a male/female ratio of 17:16 in DSAEK/DSEK/DMEK group (no gender information for 10 cases). Of the 62 cases, 46 cases (75.41%) were fungal, 9 cases (14.75%) were bacterial, 2 cases (3.28%) were Actinomyces species, 1 case (1.64%) was acanthamoeba, and 4 cases (6.56%) were indeterminant. The mean onset of symptoms was postoperative day (POD) 49.47 ± 48.56 in DALK/ALK group, and 53 ± 112.01 in EK group, and 62.44 ± 50.07 for the bacterial keratitis, and 51.5 ± 102.42 for fungal keratitis. The mean postoperative follow-up period was 10.10 ± 9.36 months in DALK/ALK group and 12.37 ± 12.28 months in DSAEK/DSEK/DMEK group. Of the total 62 cases, 1 case (1.61%) with a Klebsiella pneumoniae positive donor rim cultures was associated with the same pathogen in the IIK, and 16 cases (25.81%) of fungal positive donor rim cultures were associated with the same pathogen in the IIK. Clinical signs included conjunctival injection, interface opacity, stromal edema for bacterial keratitis, and dense white infiltrates at the interface with endothelial plaques in some cases of fungal keratitis. Medical treatment included topical and oral antimicrobial agents. Surgical interventions included therapeutic keratoplasty. In 15 cases (24.19%), medical management was successful. Of the remaining 47 cases, 8 (12.90%) were managed with a repeat lamellar keratoplasty (LK) and 39 (62.90%) were unresponsive to conservative medical treatment and underwent a therapeutic keratoplasty (TKP). Post infectious best corrected visual acuity (BCVA) was logMAR 0 in 7 eyes (11.29%), better than or equal to logMAR 0.4 in 20 eyes (32.26%), less than logMAR 0.4 in 22 eyes (35.48%) and logMAR 0.7 or worse in 13 eyes (20.97%). In the rim culture negative group(n = 19), the average BCVA was logMAR 0.59 ± 0.68, with was logMAR 0.44 ± 0.74 in rim culture positive group (n = 15). There were three recurrence cases were reported after DMEK during the postoperative follow-up period.
    Infectious interface keratitis (IIK) is an uncommon complication of lamellar keratoplasty, but it can result in a substantial loss of vision or permanent blindness. Although graft infection can occur at any time following surgery, it most commonly (87%) occurred during the first 3 months postoperatively (54/62 cases). The most commonly reported causative organism of IIK following lamellar keratoplasty was C. albicans. Positive rim culture results can provide more rapid and appropriate treatment directed to the identified organism. Therapeutic keratoplasty (TKP) was the most common surgical procedure for the management of IIK. Visual outcomes post TKP are fair with 32.26% (20/62) of patients obtaining LogMAR 0.4 or better.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    OBJECTIVE: To evaluate the efficacy and safety of descemet stripping automated endothelial keratoplasty (DSAEK) compared with descemet membrane endothelial keratoplasty (DMEK).
    METHODS: Databases including PubMed, EMBASE, and Cochrane Library were searched to find studies that compared DSAEK and DMEK outcomes. Efficacy parameters were the postoperative best-corrected visual acuity (BCVA) and spherical equivalent (SE). Safety parameters were postoperative endothelial cell loss (ECL), air injection (rebubbling), graft failure, graft rejection, and high intraocular pressure (IOP). Results from last visit were pooled for the analyses because the follow-up ranged from 3 to 24 months.
    RESULTS: A total of 7 trials including 433 eyes were selected for this meta-analysis. BCVA was reported in all 7 studies, ECL% and rebubbling rate were reported in 6, and the remaining outcomes were reported in only 3 or 2 studies. Postoperative logMAR BCVA was significantly better for DMEK than that for DSAEK (P < 0.00001). More patients achieved the postoperative BCVA ≥ 20/25 and 20/20 in DMEK group than that in DSAEK (P > 0.001), whereas the proportion of patients whose postoperative BCVA ≥ 20/40 and the amount of SE did not differ statistically (P = 0.32 and P = 0.50, respectively). The DSAEK group has a significantly lower frequency of rebubbling than the DMEK group (P < 0.0001). The postoperative ECL%, graft failure, graft rejection, and high IOP were comparable between the 2 groups (all P values >0.05).
    CONCLUSIONS: Our meta-analysis suggests that DMEK provided better visual outcomes with similar safety when compared to DSAEK. Given the limited sample size, further investigations are needed to validate these findings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号